Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relapsingremitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

Ghezzi, A., Grimaldi, L.M., Marrosu, M.G., Pozzilli, C., Comi, G., Bertolotto, A., et al. (2011). Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. NEUROLOGICAL SCIENCES, 32(2), 351-358 [10.1007/s10072-010-0469-0].

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

SAVETTIERI, Giovanni;
2011-01-01

Abstract

Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relapsingremitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
Settore MED/26 - Neurologia
Ghezzi, A., Grimaldi, L.M., Marrosu, M.G., Pozzilli, C., Comi, G., Bertolotto, A., et al. (2011). Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. NEUROLOGICAL SCIENCES, 32(2), 351-358 [10.1007/s10072-010-0469-0].
File in questo prodotto:
File Dimensione Formato  
Natalizumab therapy of multiple sclerosis.pdf

Solo gestori archvio

Dimensione 233.49 kB
Formato Adobe PDF
233.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/55497
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact